Lymphoma
| Primary Site | Histology | Behavior | Schema Discriminator 1 | Year of Diagnosis |
|---|---|---|---|---|
| C000-C424, C470-C509, C511-C608, C619-C631, C637-C689, C691-C694, C698-C699, C739-C749, C760-C809 | 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 | <Any value> | <Any value> | <Any value> |
| C440, C442-C449, C510, C609, C632 | 9590, 9596, 9650-9663, 9673-9679, 9687-9699, 9702-9705, 9714-9717, 9725, 9735, 9737-9738 | <Any value> | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9590, 9596-9663, 9673-9679, 9687-9689, 9691-9698, 9716-9718, 9725-9726, 9735, 9737-9738 | 3 | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9690, 9719 | 3 | <Any value> | 2018-2022 |
| C750, C754-C759 | 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 | <Any value> | <Any value> | <Any value> |
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9591 | <Any value> | 3, 9 | <Any value> |
| C700-C729, C751-C753 | 9591 | 3 | 3, 9 | <Any value> |
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9826-9827 | <Any value> | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9826-9827 | 3 | <Any value> | <Any value> |
Notes
9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9826-9827 (varying primary sites and histologies) * C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See **Note 2**) C000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9 *See SSDI Manual, Appendix A: Schema ID 00790: Lymphoma for detailed listing of primary site/histology combinations for this schema* **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Histologies moved to Brain, CNS, Intracranial Gland** * For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland schemas starting with 2023 diagnoses. * If you have one of these cases for 2018-2022, then this is the appropriate schema. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate schema * 9690, 9719 * **Brain**: C700, C710-C719 * **CNS Other**: C701, C709, C720-C725, C728-C729 * **Intracranial Gland**: C751-C753 **Note 3:** **Other EOD Schemas with the listed histologies** * **Brain**: C700, C710-C719 (9680, 9699, 9702-9715) * **CNS Other**: C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715) * **Heme Retic**: 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809) * **Intracranial Gland**: C751-C753 (9680, 9699, 9702-9715) * **Lymphoma CLL/SLL**: C000-C440, C442-C689, C691-C694, C698-C809 (9823) * **Lymphoma Ocular Adnexa**: C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930) * **Primary Cutaneous Lymphoma**: C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas* **Note 4:** **Lugano Staging** * The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. * The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). * A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 5:** **Schema includes the preferred terms based on the 2024 WHO Classification of Tumours, Haematolymphoid tumors, 5th edition** * 9590: Malignant lymphoma, NOS * 9591: Malignant lymphoma, non-Hodgkin, NOS * 9596: Mediastinal grey zone lymphoma (MGZL) * 9597: Primary cutaneous follicle centre lymphoma (PCFCL) * 9650: Classic Hodgkin lymphoma (cHL), NOS * 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL) * 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL) * 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL) * 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) * 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) * 9673: Mantle cell lymphoma (MCL) * 9678: Primary effusion lymphoma (PEL) * 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL) * 9680: Diffuse large B-cell lymphoma (DLBCL) * 9687: Burkitt lymphoma (BL), NOS * 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) * 9689: Splenic marginal zone lymphoma (SMZL) * 9690 Follicular lymphoma (FL), NOS (except C700-C729, C751-C753 for 1/1/2023+) * 9691: Follicular lymphoma, grade 2 * 9695: Follicular lymphoma, grade 1 * 9698: Follicular lymphoma, grade 3 * 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) * 9702: Peripheral T-cell lymphoma, NOS * 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type * 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) * 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL) * 9712: Intravascular large B-cell lymphoma (IVLBCL) * 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL) * 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) (2021+ only) * 9716: Hepatosplenic T-cell lymphoma (HSTCL) * 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS) * 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL) * 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+) * 9725: Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021) * 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) (2018-2020 only, see code 9687/3 for 2021+) * 9735: Plasmablastic lymphoma (PBL) * 9737: ALK-positive large B-cell lymphoma (ALK+LBCL) * 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma * 9826: Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+) * 9827: Adult T-cell leukemia/lymphoma (ATLL)Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Schema Discriminator 1 | Yes |
NAACCR #3926
schemaDiscriminator1 |
All | SSDI | |
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | 999 | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | 999 | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| Neoadjuvant Therapy | 0 | No |
NAACCR #1632
neoadjuvantTherapy |
None | |
| Neoadjuvant Therapy – Clinical Response | 0 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
None | |
| Neoadjuvant Therapy – Treatment Effect | 0 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 88 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 8 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 8 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| B Symptoms | 8 | No |
NAACCR #3812
bSymptoms |
CCCR/Canada COC SEER 2018–2025 SEER (RC) 2026– |
SSDI |
| HIV Status | 8 | No |
NAACCR #3859
hivStatus |
COC 2018–2020 SEER |
SSDI |
| NCCN International Prognostic Index (IPI) | X8 | No |
NAACCR #3896
nccnInternationalPrognosticIndex |
COC SEER 2018–2025 SEER (RC) 2026– |
SSDI |
| PTLD | 8 | No |
NAACCR #1172
ptld |
COC 2025– NPCR 2025– SEER 2025– |
SSDI 2025– |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 00790 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |